Cargando…

CMTM3 Overexpression Predicts Poor Survival and Promotes Proliferation and Migration in Pancreatic Cancer

Background: Recent evidence has shown that CKLF-like MARVEL transmembrane domain containing 3 (CMTM3) promoted carcinogenesis and tumor progression in a variety of cancer types. The goal of our study is to investigate the association between CMTM3 and pancreatic cancer (PC). Materials and Methods: I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Zixuan, Ma, Zuyi, Li, Zhenchong, Zhuang, Hongkai, Liu, Chunsheng, Gong, Yuanfeng, Huang, Shanzhou, Zhang, Chuanzhao, Hou, Baohua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408105/ https://www.ncbi.nlm.nih.gov/pubmed/34475993 http://dx.doi.org/10.7150/jca.57082

Ejemplares similares

Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy
por: Zhuang, Hongkai, et al.
Publicado: (2021)

Characterization of the prognostic and oncologic values of ITGB superfamily members in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8(+) T cells in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Identification of Prognostic and Therapeutic Biomarkers among FAM83 Family Members for Pancreatic Ductal Adenocarcinoma
por: Ma, Zuyi, et al.
Publicado: (2021)

Prognostic Stratification Based on HIF-1 Signaling for Evaluating Hypoxic Status and Immune Infiltration in Pancreatic Ductal Adenocarcinomas
por: Zhuang, Hongkai, et al.
Publicado: (2021)

ZMAT1 acts as a tumor suppressor in pancreatic ductal adenocarcinoma by inducing SIRT3/p53 signaling pathway
por: Ma, Zuyi, et al.
Publicado: (2022)

Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer
por: Ma, Zuyi, et al.
Publicado: (2021)

A four prognosis-associated lncRNAs (PALnc) based risk score system reflects immune cell infiltration and predicts patient survival in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Identification by genetic algorithm optimized back propagation artificial neural network and validation of a four-gene signature for diagnosis and prognosis of pancreatic cancer
por: Li, Zhenchong, et al.
Publicado: (2022)

Identification of MBOAT2 as an Unfavorable Biomarker Correlated with KRAS Activation and Reduced CD8(+) T-Cell Infiltration in Pancreatic Cancer
por: Li, Zhenchong, et al.
Publicado: (2022)

A Novel Prognostic Nomogram for Gallbladder Cancer after Surgical Resection: A Single-Center Experience
por: Ma, Zuyi, et al.
Publicado: (2021)

Prognostic Stratification Based on a Novel Nomogram for Solitary Large Hepatocellular Carcinoma After Curative Resection
por: Zhuang, Hongkai, et al.
Publicado: (2020)

SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma
por: Ma, Zuyi, et al.
Publicado: (2021)

Prognostic values and immune suppression of the S100A family in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2021)

A hierarchical prognostic model for Co-diabetes pancreatic adenocarcinoma
por: Wu, Zelong, et al.
Publicado: (2023)

Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
por: Huang, Shanzhou, et al.
Publicado: (2022)

GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8(+) T cells infiltration in pancreatic cancer
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma
por: Huang, Shanzhou, et al.
Publicado: (2020)

Incidental intraoperative finding of gallbladder duplication in a patient with a choledochal cyst
por: Zhuang, Hongkai, et al.
Publicado: (2020)

Neo-adjuvant chemotherapy followed by radical resection for primary borderline resectable unicentric Castleman disease: a case report
por: Zhuang, Hongkai, et al.
Publicado: (2020)

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
por: Guan, Xiudong, et al.
Publicado: (2018)

Establishment and validation of an AJCC stage- and histologic grade-based nomogram for pancreatic neuroendocrine tumors after surgical resection
por: Zhang, Chuanzhao, et al.
Publicado: (2019)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

CMTM5-v1 inhibits cell proliferation and migration by downregulating oncogenic EGFR signaling in prostate cancer cells
por: Yuan, Yeqing, et al.
Publicado: (2020)

Overexpression of GIHCG is Associated with a Poor Prognosis and Immune Infiltration in Hepatocellular Carcinoma
por: Xiao, Siyu, et al.
Publicado: (2020)

CMTM6 as a potential therapy target is associated with immunological tumor microenvironment and can promote migration and invasion in pancreatic adenocarcinoma
por: Gao, Hongli, et al.
Publicado: (2023)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
por: Su, Yu, et al.
Publicado: (2014)

CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells
por: Huang, Xiaoting, et al.
Publicado: (2021)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

Overexpression of microRNA-423-3p indicates poor prognosis and promotes cell proliferation, migration, and invasion of lung cancer
por: Wang, Rukun, et al.
Publicado: (2019)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

Overexpression of CASC19 indicates poor prognosis and facilitates proliferation, migration and invasion in colorectal cancer
por: Zhao, Jiang, et al.
Publicado: (2019)

Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma
por: Wang, Xianming, et al.
Publicado: (2019)

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer
por: Xue, Hui, et al.
Publicado: (2022)

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer
por: Si, Jiahui, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v8a6hq9hc3dtvtri99kk074vbo